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A B S T R A C T
The ICH quality vision introduced the concept of quality by design (QbD), which requires a greater
understanding of the raw material attributes, of process parameters, of their variability and their
interactions. Microcrystalline cellulose (MCC) is one of the most important tableting excipients thanks to
its outstanding dry binding properties, enabling the manufacture of tablets by direct compression (DC).
DC remains the most economical technique to produce large batches of tablets, however its efﬁcacy is
directly impacted by the raw material attributes. Therefore excipients’ variability and their impact on
drug product performance need to be thoroughly understood. To help with this process, this review
article gathers prior knowledge on MCC, focuses on its use in DC and lists some of its potential critical
material attributes (CMAs).
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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The International Conference on Harmonisation (ICH) of
Technical Requirements for Registration of Pharmaceuticals for
Human Use has set a new quality paradigm as described in its
guidelines Q8(R2), Q9, and Q10. The new paradigm promotes
science and risk-based approaches to product development,
dossier submission, review, inspection and post-approval change
management. Furthermore, manufacturers are now encouraged to
effect continuous improvement and technical innovation through-
out the product life cycle.
The ICH quality vision impacts not only drug manufacturers but
others in the pharmaceutical supply chain. Excipients, and therefore
excipients suppliers, play an important and sometimes critical role
with regard to drug product quality (Kushner, 2013). It is now
paramount to identify, understand and control excipient variability,
so that it can be compensated or controlled to deliver consistent
product quality (ICH, 2005, 2009). Excipient performance is rarely
fully understood (Moreton, 2009c; Wang et al., 2013) and at times
underestimated (Carlin, 2012; Friedman, 2011). This is true even for
one of the most popular tablet diluents used in the most
straightforward process to produce oral solid dosage forms, namely
microcrystalline cellulose (MCC) in direct compression (DC).
Direct compression (DC) is the tableting of a blend of
ingredients without a preliminary granulation or agglomeration
process. Despite involving only few process steps, product design
in DC can be challenging because of the numerous competing
objectives (Peck et al., 1990). Among several requirements, the
compression mix has to ﬂow to ensure a consistent tablet weight;
it has to compress and compact into robust tablets; and the
resulting tablets have to remain stable over time to maintain safety
and efﬁcacy. DC is directly impacted by material properties since
these are not altered by preceding process steps. Therefore, direct
compression requires increased performance, quality and consis-
tency from the starting ingredients including excipients (Carlin,
2008; Kása et al., 2009; Patel et al., 2006; Tho and Bauer-Brandl,
2011). The use of poorly controlled or inadequately speciﬁed raw
materials may lead to several challenges in DC, such as poor
ﬂowability and inconsistent tablet weight, unsatisfactory tablet
strength, lack of content uniformity or segregation and dissolution
failure (Friedman, 2011; Hentzschel et al., 2012; Ilic et al., 2013;
McCormick, 2005; Patel et al., 2006).
Diluents are incorporated into tablet or capsule dosage forms to
increase dosage form volume or weight, and as such they can also
be referred to as ﬁllers (USP37-NF32, 2014a). Some diluents, such
as microcrystalline cellulose (MCC), can also be considered as dry
binders since they improve the compactibility or tabletability of
the compression mix. True DC binders are functional even at low
use levels and offer superior tabletability (Carlin, 2008). Most DC
grade excipients also offer superior ﬂow compared to grades used
in granulation techniques.
The scale of manufacture of excipients is very different from that
typically encountered in pharmaceutical product manufacture.
Indeed in continuous production, a ‘batch’ is usually a time period
or slice (days) from a larger production campaign (weeks) (Carlin,
2012), but even days or weeks of productioncanstill amount to many
tons. Considering these large batch sizes and the intrinsic variability
of continuous processes, intra-batch (container-to-container) vari-
ability is inevitable (Hoag, 2011; Moreton, 2006). For this reason,
traceability of individual containers to the nearest relevant in-
process results is essential. Additional excipient variability can be
caused by (1) the seasonal quality variation of raw materials having
natural origins and (2) the sourcing from multiple suppliers or from
multiple sites, each of them using different processes (with or
without processing aids), which may create issues due to perfor-
mance disparities (Sheehan, 2012; Sheehan and Amidon, 2011).The purpose of this review article is (1) to thoroughly describe
MCC and its behavior in direct compression, (2) to highlight the
need for a greater understanding of excipient variability and
excipient performance, and (3) to gather prior knowledge relating
to some possible critical material attributes (CMAs) of MCC when
used in direct compression.
2. Microcrystalline cellulose, a direct compression binder
Microcrystalline cellulose (MCC) was discovered in 1955 by
Battista and Smith and was ﬁrst commercialized under the brand
name Avicel1 (FMC, 2013). In 1964 FMC Corporation introduced
Avicel1 PH to the pharmaceutical industry as an ingredient for
direct compression tableting (Albers et al., 2006). MCC was ﬁrst
registered in the supplement to the National Formulary, twelfth
edition, in 1966 (Suzuki and Nakagami, 1999). More than 50 years
later, MCC is manufactured globally by more than 10 suppliers.
MCC is a puriﬁed, partially depolymerized cellulose prepared by
treating alpha cellulose (type Ib), obtained as a pulp from ﬁbrous
plant material, with mineral acids. Cellulose is the most abundant
natural polymer on earth with an annual biomass production of 50
billion tons (Carlin, 2008). Cellulose consists of linear chains of
b-1,4-D anhydroglucopyranosyl units.
The most common source of pharmaceutical MCC is wood, in
which cellulose chains are packed in layers held together by a
cross-linking polymer (lignin) and strong hydrogen bonds. Cotton
has also been mentioned as a possible cellulose source for MCC
(Shlieout et al., 2002; Suzuki and Nakagami, 1999). Both softwoods
(evergreen conifer) and hardwoods (deciduous broadleaf) can be
used (Landín et al., 1993a). These woods differ considerably in
chemical composition (proportions of cellulose, hemicelluloses
and lignin) and structural organization, i.e., regions which are
relatively more crystalline or amorphous. The amorphous regions
are more prone to hydrolysis so partial depolymerization by acid
hydrolysis results in shorter and more crystalline fragments, i.e.,
microcrystalline cellulose.
Degree of polymerization (DP), i.e., the number of glucose units
(C6H10O5)n in the cellulose chain, exponentially decreases as a
function of hydrolysis conditions, which include temperature, acid
concentration and time. The rate of hydrolysis slows to a certain
level-off degree of polymerization (LODP). The LODP is a
characteristic of a particular pulp and is typically found in the
200–300 range (Doelker, 1993), e.g., 180–210 range for hardwood
pulps and 210–250 for softwood pulps. In theory, hydrolysis could
be terminated at any time to obtain a degree of polymerization
higher than the LODP. However this is neither a robust nor a
reproducible approach considering the exponential decay of DP.
The reduction of degree of polymerization with hydrolysis time is
shown in Fig. 1 (courtesy of FMC Health and Nutrition). Degree of
polymerization is used as an identity test, as pharmacopoeial MCC
is deﬁned by a DP below 350 glucose units, compared to DPs in the
order of 10,000 units for the original native cellulose (Carlin, 2008;
Dybowski, 1997).
MCC is commonly manufactured by spray drying the neutralized
aqueous slurry resulting from the hydrolysis of cellulose. Most
commercial grades are formed by varying and controlling the spray
drying conditions in order to manipulate the degree of agglomera-
tion (particle size distribution) and moisture content (loss on
drying). Other drying techniques may be used, which may require
additional screeningstepspostdrying inorder to control particlesize
distribution. Higher bulk density grades are also available by using
speciﬁc cellulose pulps (raw material), and median particle sizes
below 50 mm can be obtained by further milling MCC (Carlin, 2008).
MCC is generally considered as the diluent having the best
binding properties and is recognized as one of the preferred DC
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Fig. 1. LODP of softwood pulps.
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excipients, MCC is self-disintegrating (Ferrari et al., 1996) with
low lubricant requirement due to its extremely low coefﬁcient of
friction and its very low residual die wall pressure (Hwang and
Peck, 2001; Patel et al., 2006; Saigal et al., 2009). However these
properties do not replace the need for true disintegrants and
lubricants when MCC is used in a formulation. In fact MCC and
superdisintegrants may be complementary to promote fast
disintegration (Bala et al., 2013; Mostafa et al., 2013). MCC
offers other advantages including broad compatibility with APIs,
physiological inertness, ease of handling, and security of supply
(Bolhuis and Chowhan, 1996).
During compression MCC plastically deforms and therefore
maximizes the area of interparticle bonding (Rubinstein, 1988).
Porous, often spray-dried, agglomerates deform on a macroscale;
then due to the presence of slip planes, MCC dislocates on a
microscale (Carlin, 2008; Haware et al., 2009). This proximity of
hydrogen groups on adjacent cellulose molecules enables the
formation of numerous hydrogen bonds, which account almost
exclusively for the strength and cohesiveness of compacts, even
under low compression forces (Bolhuis and Chowhan, 1996; Carlin,
2008; Saigal et al., 2009). Mechanical interlocking of irregularly
shaped and elongated MCC particles has also been suggested to
enhance tabletability (Doelker,1993; Nyström et al.,1993; Pesonen
and Paronen, 1990; Westermarck et al., 1999).
The plasticity of MCC is the main reason of its exceptional
binding properties. However, compared to brittle excipients, MCC
is more lubricant sensitive. Lubricated MCC particles will deform
under pressure and will not fracture to create new and clean
(lubricant-free) surfaces (Hoag et al., 2008; Wang et al., 2010;
Zuurman et al., 1999). The presence of high levels of hydrophobic
lubricants, such as magnesium stearate, the use of long blend times
and high blend speeds would then result in softer tablets (Bolhuis
and Chowhan, 1996). For a constant number of revolutions,
tabletability may also decrease with increasing blender sizes and
decreasing loadings in the blender (Kushner and Moore, 2010).
Furthermore the transit of the lubricated blend via the hopper and
the feed frame of tablet presses may result in additional coverage
of lubricant over the MCC particles (Narang et al., 2010; Otsuka
et al., 2004). The addition of brittle excipients and/or colloidal
silicon dioxide to blends containing MCC can successfully prevent
lubricants to occupy the MCC surfaces, and would in turn minimize
the negative inﬂuence of these lubricants on tablet strength (de
Lourdes Garzón and Villafuerte, 2002; van Veen et al., 2005).
The viscoelastic behavior of MCC also explains its Strain Rate
Sensitivity (SRS), which refers to the greater elastic effects athigher tableting speeds where there is insufﬁcient compaction
time for plastic deformation (Roberts and Rowe, 1985). In other
words, the tabletability of MCC always decreases when scaled up
from slow development tablet presses to high speed production
rotary machines. The Strain Rate Sensitivity of viscoelastic
excipients has to be taken into account by the formulation
scientists in order to design robust formulations. The MCC content
should not be minimized based on low speed trials alone. Sufﬁcient
overage should be included to compensate for increased elastic
effects at higher speeds. Despite the lower tabletability of brittle
excipients, which fragment in a time-independent manner, these
excipients have been widely combined with plastically deforming
binders to minimize the overall Strain Rate Sensitivity of
formulations and to facilitate scale-up.
Thanks to its relatively low bulk density and broad particle size
distribution, small amounts of MCC are able to efﬁciently bind
other materials, especially poorly tabletable active pharmaceutical
ingredients. MCC exhibits a high dilution potential, whereas the
broad particle size range provides optimum packing density and
coverage of other materials (Bolhuis and Chowhan, 1996; Carlin,
2008).
MCC type 102, having a median particle size of about 100 mm (D50
value measured by laser diffraction), presents acceptable ﬂow
properties required for successful high speed tableting (Shi et al.,
2011; Shlieout et al., 2002). However due to the low bulk density of
MCC, its mass ﬂow is less than that of other common and denser
excipients such as direct compression grades of lactose or dibasic
calcium phosphates (Albers et al., 2006; Doelker, 1993; Hentzschel
etal.,2012; Jivrajet al.,2000).The differencebetweenthesecommon
excipients is less pronounced on a volumetric basis (Wallace et al.,
1983), which determines dieﬁll. Flowability may of course be further
improved by selecting coarser grades of MCC with a larger number of
aggregates, such as MCC type 200 with a median particle size
approximating 200 mm (Gamble et al., 2011; Lahdenpää et al.,1997).
Another approach may be to combine MCC with other free ﬂowing
excipientsorglidants (Hwang and Peck, 2001; Jivraj et al., 2000;Patel
et al., 1994). Gamble et al. observed that the particle size
distributions of coarser grades of MCC do not scale up proportionally
(Gamble et al., 2011). MCC types 101, 102 and 200 all have primary
particles of about 50 mm but differ in the number of larger
aggregated particles. These aggregates, accounting for a large
volume/mass fraction but a low number fraction, enable improved
ﬂow. Scanning electron micrographs of Avicel1 PH-101 and Avicel1
PH-102 are shown in Fig. 2 (Gamble et al., 2011).
MCC has a very high intraparticle porosity with approximately
90–95% of the surface area being internal (Doelker, 1993).
Therefore surface area is not directly inﬂuenced by the nominal
particle size (Gamble et al., 2011). This high porosity promotes
swelling and disintegration of MCC tablets, which is attributed to
the penetration of water into the hydrophilic tablet matrix by
means of capillary action of the pores and by a subsequent
disruption of the hydrogen bonds. Increasing compaction
pressure decreases water penetration into the tablets and
increases disintegration time (Bolhuis and Chowhan, 1996;
Lahdenpää et al., 1997). Similarly MCC densiﬁed via an extrusion
process tends to disintegrate very slowly without the presence of
a superdisintegrant or of a pore former (Chamsai and Sriamorn-
sak, 2013).
MCC is a stable though hygroscopic material, which can be
attributed to the presence of abundant hydroxyl groups on
cellulose chains and to the relatively large surface to volume ratio
of microﬁbrils due to their small size (Guy, 2009; Sun, 2008). When
exposed to 25 C and 50% relative humidity, its equilibrium
moisture content is approximately 5%. The sorption mechanism
involves water molecules tightly bound to accessible hydroxyl
groups of the anhydroglucose units, followed by a second less
Fig. 2. Scanning electron micrographs of Avicel1 PH-101 (left) and Avicel1 PH-102 (right).
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is only sorbed in the amorphous regions of MCC, which are more
hydrophilic than the crystalline regions (Bolhuis and Chowhan,
1996; Suzuki and Nakagami, 1999). Therefore it is proposed that
the total amount of sorbed water is proportional to the fraction of
amorphous material and is independent of the surface area
(Amidon and Houghton, 1995). The crystallinity of MCC deter-
mined by X-ray diffraction and infrared measurement is about 60–
80% (Bolhuis and Chowhan, 1996; Sun 2008).
The presence of free hydroxyl groups on the surface of MCC
tablets (or pellets) also provide excellent binding sites for cellulosic
ﬁlms, which are common coating polymers (Felton and McGinity,
1999; Khan et al., 2001). This results in improved ﬁlm adhesion and
strength. However the inability of lubricated MCC to create clean
and uncontaminated surfaces during compression may negatively
impact ﬁlm adhesion (Rowe, 1977; Wang et al., 2010).
MCC may contain low levels of non-saccharide organic residues.
These originate from lignin, a cross-linked biopolymer, which is
hydrophobic and aromatic in nature (Crowley and Martini, 2001).
As a result of the pulp deligniﬁcation process, it is possible that
lignin breakdown products may be present in MCC. These will be
derivatives of the three main monolignols that compose lignin:
coniferyl alcohol, sinapyl alcohol and paracoumaryl alcohol. Some
other minor components may include cellulose type II, hemi-
celluloses, sugar residues resulting from the hydrolysis, peroxides
from the pulping process, and trace ammonia used to neutralize
the acid from the hydrolysis step (Moreton, 2009c; Wasylaschuk
et al., 2007). The reducing sugars and the reactive glucose end
group on each cellulose chain may also exhibit keto-enol
tautomerism via an aldehyde intermediate. Too aggressive a
method of aldehyde determination, e.g., long exposure to acids and
high temperature, may generate false positives by stripping end
glucose groups from the cellulose chain, giving a higher apparent
aldehyde content (Wu et al., 2011). Formaldehyde is not used in
MCC manufacture; however at a ppm level of scrutiny, all cellulosic
excipients will exhibit trace aldehyde reactions.
In addition to various minor components, MCC produced by
various manufacturers or in various manufacturing sites may have
different properties due to the kinds of pulp used as raw materials
and their respective manufacturing conditions (Landín et al.,
1993a; Shlieout et al., 2002). These different properties or
attributes may affect the tabletability of MCC. Several studies
conﬁrmed that despite some batch-to-batch variation, the major
performance differences were observed between multiple man-
ufacturers (Albers et al., 2006; Doelker, 1993; Doelker et al., 1987;
Landín et al., 1993a,b,c; Williams et al., 1997).Albers et al. evaluated the tableting properties of three batches
from ﬁve different brands MCC type 101 (Albers et al., 2006). As
expected the batches from a single manufacturer were more
similar than the samples from various sources; however, statisti-
cally signiﬁcant differences were also observed within single
brands of MCC. The greatest differences in powder properties were
observed in the median particle size and speciﬁc surface area.
Despite the lower median particle size of Avicel1 PH-101 (FMC)
compared to other brands, this MCC was described as easy ﬂowing
as illustrated by a low compressibility index and shear cell ﬂow
functions (FFc) values exceeding 4. Particle shape or morphology
was not assessed in this study, but one could imagine particle
morphology to be inﬂuenced partly by the drying conditions and
would most probably vary between each manufacturer. No
correlation could be found between particle size, speciﬁc surface
area and tablet strength. However spray dried MCC provided
acceptably low tablet friability. It was concluded that the MCC
brands cannot be directly substituted by other brands based on the
physico-mechanical properties examined.
Williams et al. used tableting indices to investigate the
compaction properties of MCC types 101 and 102 (median particle
size of about 50 and 100 mm, respectively), each type being
represented by two batches from 5 different sources (Williams
et al., 1997). Spray dried MCCs presented most similarities and
negligible batch-to-batch differences, whereas MCCs from other
sources, and most certainly processed in a different manner, were
less consistent. The importance of completely characterizing and
evaluating each MCC product prior to use in a tablet formulation
was highlighted. It was also suggested that differences in the
compaction properties of various MCCs may impact tablet
formulation robustness, and may require the formulation to be
further optimized to cope with this variability.
Landín et al. compared four brands of MCC (Landín et al.,
1993b). Compositional differences in lignin and hemicelluloses
suggested that different woods were used as raw materials, i.e.,
hardwood versus softwood. These non-cellulose components were
also suggestive of manufacturing processes of signiﬁcantly
different intensities, which resulted in variable composition and
potentially varying qualities. In a subsequent study, Landin et al.
found that lignin content increased the dissolution rate of
prednisone (Landín et al., 1993c). Lignin being hydrophobic may
alter cellulose–cellulose and/or cellulose–API interactions and
hence drug release rate.
Doelker et al. conducted one of the most complete studies by
comparing sixteen MCCs from seven manufacturers (Doelker et al.,
1987). Differences in packing and in ﬂow properties were
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particle size distribution. Tabletability also varied among the MCC
samples and was attributed partly to differences in moisture
content and in the internal structure of the particles caused by
processing conditions speciﬁc to each manufacturer. The impact of
crystallinity and particle morphology was however deemed
negligible. Signiﬁcant differences in lubricant sensitivity, in
compressibility and in tablet disintegration were also noted
between MCCs from various manufacturers. In contrast, variability
between lots from the same manufacturer was smaller. In another
paper Doelker concluded that large differences exist among
various MCCs, even if all of them comply with compendial
speciﬁcations (Doelker, 1993). Therefore substitution of one
product for another must be validated.
3. Understanding excipient variability and performance
In light of the quality by design (QbD) initiative, detailed
understanding of the impact of raw material variability on the
performance and manufacturability of new drug products is now a
signiﬁcant concern (Kushner, 2013; Kushner et al., 2011). The
potential impact of APIs and of their variability is undeniable.
However excipients form also an important and maybe critical part
of any pharmaceutical formulation (Moreton, 2010). Unfortunately
the principles that govern how excipient properties inﬂuence the
critical quality attributes (CQAs) of a drug product are rarely
understood. The interactions of excipient attributes with other raw
materials and with manufacturing processes render the situation
even more complex (Wang et al., 2013). The creation of excipient
databases, such as the PharmaHUB, and review articles may help
closing this gap by providing prior knowledge to formulation
scientists.
An excipient is included in a drug product to impart
functionality. Excipient functionality can be deﬁned as a desirable
property that aids and/or improves the manufacture, quality, or
performance of the drug product (IPEC, 2008). Functionality is a
broad, qualitative, and descriptive term for the general purpose or
role an excipient serves in a formulation (Sheehan, 2011; USP37-
NF32, 2014a). Excipient performance refers to the outcome in the
ﬁnished product, which is not only determined by the intrinsic
properties of an excipient but also depends on formulation and
processing effects that inﬂuence an excipient's ability to perform
its intended functional purpose (Carlin and Moreton, 2010;
Sheehan, 2011).
MCC, as any pharmaceutical excipient, needs to meet its
compendial speciﬁcations, i.e., a minimum set of speciﬁcations
for identity, quality, and purity (Moreton, 2009a; Sheehan, 2012).
However, since these tests do not consider the application nor the
purpose of the excipient, Pharmacopoeial attributes might not be
the critical material attributes (CMAs) (Albers et al., 2006; Carlin,
2012; Carlin and Moreton, 2010; Pifferi et al., 1999; Whiteman
and Yarwood, 1988). Considering it may be difﬁcult for excipient
suppliers to provide an ideal set of samples to the pharmaceutical
manufacturers to adequately investigate the impact of excipient
material properties on drug product performance (Kushner et al.,
2014; Moreton, 2009b), some excipient variability may nonethe-
less be captured by the compendial attributes listed on the
certiﬁcate of analysis (CoA) (Kushner, 2013; Moreton, 2009c).
However it is important to realize that, for high volume
continuously produced excipients, CoA values may understate
the true variability as they may be averages of in-process data or
derived from composite samples, i.e., blends of in-process
samples.
Since the relevance of excipient attributes may differ in each
formulation and manufacturing process (Díaz Ramírez and Robles,
2010; Sheehan and Amidon, 2011), the users are responsible toidentify the critical material attributes of the excipient for their
particular application, and if necessary to set the appropriate
speciﬁcations (Carlin et al., 2007; Moreton, 2009a; Tho and Bauer-
Brandl, 2011). To ensure consistent excipient performance in a
particular application, one should fully understand the physico-
chemical properties, the composition, the method of manufacture,
and the supplier process capability for each excipient (Carlin et al.,
2007; Moreton, 2009a). Only then can the appropriate Control
Strategies be established to guarantee that the drug product
critical quality attributes (CQAs) are maintained throughout the
product life cycle (Sheehan, 2012). In order to achieve this level of
understanding, early discussion with excipient suppliers is
advisable (IPEC, 2008).
According to the European Pharmacopoeia (Ph.Eur. 8.0, 2014)
potential CMAs, called functionality-related characteristics (FRCs),
of MCC used as binder, diluent or disintegrant may include particle
size distribution and ﬂowability. The non-mandatory USP infor-
mation chapter on excipient performance lists additional physical
properties relevant to tablet diluents, and therefore to MCC, and
includes: (1) particle size and size distribution, (2) particle shape,
(3) bulk/tapped/true density, (4) speciﬁc surface area, (5)
crystallinity, (6) moisture content, (7) powder ﬂow, (8) solubility
(MCC is insoluble in water), and (9) compaction properties for
tablet dosage forms (USP37-NF32, 2014a). This list is not
exhaustive. Additional methods, together with a set of veriﬁed
physical models that link physical properties to processing
behavior and ﬁnal product performance, could provide scientists
with comprehensive databases of properties for commonly used
excipients (Hlinak et al., 2006). Although the compaction
properties of tablet diluents are considered as relevant, and
guidelines can be found to assess tablet strength (Podczeck, 2012;
USP37-NF32, 2014b), no recommendations are currently made as
to how to prepare powder samples or blends and how to compress
them, which makes comparisons with literature values difﬁcult
(Edge et al., 2000). Standardized compaction tests could be useful
to evaluate dry binders, such as MCC, and to ensure excipient
suppliers and users speak the same language while assessing
excipient performance.
4. Potential critical material attributes of microcrystalline
cellulose
The interdependence of material properties and their poten-
tial impact on product attributes and processing behavior has
been summarized by Hlinak et al., as shown in Table 1 (Hlinak
et al., 2006).
Forexample, powder ﬂow is inﬂuencedby particle sizeandshape,
bulk density, surface area and several other material properties.
Identifying and understanding which property is truly critical is not
an easy task, especially when these properties are often interdepen-
dent. It can be expected that particle size, surface area and bulk
density are correlated. The use of multivariate analysis, such as
principalcomponentanalysis and multiple regression, ispreferredto
correlate excipients attributes with their performance (Gabrielsson
et al., 2002; Haware et al., 2009; Huang et al., 2009; Klevan et al.,
2010; Kothari et al., 2002; Kushner, 2013; Moore, 2013; Tho and
Bauer-Brandl, 2012).
In order to gather prior knowledge, the following sections
summarize studies on MCC and highlight some of its potential
critical material attributes.
4.1. Moisture content
A number of studies have conﬁrmed that the moisture content
of MCC inﬂuences compaction properties, tensile strength, and
viscoelastic properties (Amidon and Houghton, 1995; Doelker,
Table 1
Potential impact of material properties on quality attributes and processing behavior (list is not exhaustive).
Property Impact
Flow Blending Wetting Drying Mechanical Dissolution Stability
Particle size distribution X X X X X X X
Particle shape distribution X
True density X X
Bulk density – poured and tapped X X X
Pore size distribution X X X
Surface area X X X X X X X
Surface energy X X X
Flow X
Cohesiveness X X
Internal friction X X
Wall friction X X




Static charge X X
Hygroscopicity X X X
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internal lubricant, reduce frictional forces, and facilitate slippage
and plastic ﬂow within the individual microcrystals (Bolhuis and
Chowhan, 1996; Hoag et al., 2008; Nokhodchi, 2005). The
lubricating properties of water may also reduce tablet density
variation by providing a better transmission of the compression
force through the compact and by decreasing the adhesion of the
tablet to the die wall (Nokhodchi, 2005; Patel et al., 2006). Because
compressibility of MCC depends on moisture content, MCC
powders compressed to the same pressure may not result in the
same compact porosity. Indeed the compaction pressure required
to produce a compact at a certain porosity (or solid fraction)
decreases with increasing moisture content.
Sun observed that the compaction properties of MCC were
largely insensitive to moisture variation below 3% water (Sun,
2008). However an increase of moisture, up to an optimum level,
will typically increase the tablet strength of most excipients. This
may be due to the fact that bound water vapor layers reduce
interparticular surface distances and increase intermolecular
attraction forces (Patel et al., 2006). Moisture in a material may
also exert Van der Waals' forces. Above 3% water, which
corresponds to monolayer coverage, bonding strength decreases
due to the disruption of the hydrogen bonds which cross-link the
hydroxyl groups on the cellulose chains (Doelker, 1993). It can
also be said that the presence of free water reduces intermolecu-
lar attractive forces and allows separation of the particles.
However, thanks to the plasticizing effect of water and its positive
effect on bonding surface area, tabletability remains constant or
increases for moisture contents between about 3 and 5%. It has
been suggested by Sun, Amidon and Houghton that the
mechanical properties of MCC signiﬁcantly change for moisture
contents exceeding 5–6%. Above this level, the decrease in
bonding strength outplays the increase in bonding area and
results in a decrease in tabletability. A transition from the glassy
state to the rubbery state has also been proposed (Amidon and
Houghton, 1995; Sun, 2008).
The storage conditions of the MCC compacts also play an
important role, as an increase in relative humidity will negatively
impact tablet strength (Williams et al., 1997). However this
softening is often reversible when tablets are removed from the
humid environment (Carlin, 2008; Gohel, 2005).
The two fundamental forces that can affect powder ﬂow are
cohesion and friction (Nokhodchi, 2005). As moisture content
increases, frictional forces and electrostatic charges between
particles may be reduced. Moisture may also increase cohesion dueto the creation of liquid or even solid bridges between particles. In
the case of MCC, signiﬁcant changes in ﬂowability were observed
as powder cohesiveness, described by the compressibility index
and the shear cell, increased with increasing moisture contents
(Amidon and Houghton, 1995).
These observations support an upper moisture content
speciﬁcation of 5%, as it is the case with some MCC grades.
However most microcrystalline cellulose suppliers align their
speciﬁcations to the USP monograph (NF32), which states an upper
loss on drying limit of 7%.
4.2. Particle size
Particle size has very little effect on the tabletability of neat
MCC, i.e., not lubricated nor blended with other excipients or active
pharmaceutical ingredients (APIs) (Almaya and Aburub, 2008;
Gamble et al., 2011; Jivraj et al., 2000; Pesonen and Paronen, 1990).
Considering that the brittle-ductile transition diameter (Dcrit) of
MCC is 1949 mm, standard MCC grades, having particle sizes below
Dcrit, should all deform plastically when compression pressure
exceeds yield pressure (Narayan and Hancock, 2005). Coarser
grades of MCC, characterized by a smaller envelope surface area,
have been reported to be more lubricant sensitive than ﬁner MCC
(Doelker et al., 1987; Gamble et al., 2011; Hwang and Peck, 2001;
Whiteman and Yarwood, 1988).
In complete formulations ﬁner MCCs would therefore promote
tablet (compact) strength (Herting and Kleinebudde, 2007;
Kushner et al., 2011). However reducing the particle size of MCC
will certainly affect its ﬂowability, as a consequence of its increased
cohesiveness.
Kushner et al. conﬁrmed that variability in excipient particle
size may impact not only tablet hardness, friability and disinte-
gration, but also content uniformity (Kushner, 2013). Using coarser
MCCs may improve ﬂowability and reduce tablet weight variation
(Hasegawa, 2002); however, due to the increased risk of
segregation, content uniformity will not always be better. Blends
of various MCC types, having different particle size distributions,
may be considered to design robust formulations having the
optimum compromise between powder ﬂow and tabletability
(Lahdenpää et al., 1997).
In addition to the above, Hlinak et al. suggested that particle
size may also impact wetting properties, dissolution of the API and
stability of drug products (Hlinak et al., 2006). As such particle size
may be considered as one of the most important material
attributes.
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Obae et al. suggested that MCC morphology, described by the
length of particles (L) and their width (D), was one of the most
important factors inﬂuencing tabletability (Obae et al., 1999). Rod-
shaped (ﬁbrous) particles with higher L/D ratios resulted in higher
tablet strengths when compared to round-shaped particles. Other
physico-chemical properties of MCC did not correlate well with
tablet tensile strength. These properties included moisture
content, bulk density, and speciﬁc surface area. Even though not
discussed, Obae et al. also indirectly illustrated the reduction of
bulk density and ﬂowability and the increase of speciﬁc surface
area as the L/D ratio increased, i.e., as particles were more ﬁbrous.
In some cases MCC morphology may also impact drug dissolution
(Friedman, 2011).
4.4. Bulk density
Many direct compression grade excipients are spray-dried and
are therefore characterized by a porous structure and a relatively
low bulk density. This increased porosity (lower density) facilitates
compressibility, i.e., the densiﬁcation of a powder bed due to the
application of a stress (Patel et al., 2006). The improved
compressibility of plastically deforming materials, such as MCC,
might then result in improved tabletablity as a result of the
increased bonding surface area (Abdel-Hamid et al., 2011). The
higher roughness of low density MCC particles may also contribute
to particle interlocking (Liao et al., 2012). Low bulk density MCC
will have a higher dilution potential and may better counteract the
poor tableting properties of APIs. MCC densiﬁed by pre-processes
such as granulation or drying is typically less tabletable than the
original more porous MCC (Pönni et al., 2012; Westermarck et al.,
1999). It can therefore be generalized that a decrease in bulk
density improves tabletability; however, it will often hinder
ﬂowability (Hwang and Peck, 2001; Sonnergaard, 2006).
4.5. Speciﬁc surface area
The speciﬁc surface area and particle surface rugosity of
microcrystalline cellulose may positively impact its tabletability,
potentially due to the numerous hydrogen bonds between the
large bonding surface areas of adjacent particles and to the
mechanical interlocking of irregular particles (Nyström et al.,
1993; Pesonen and Paronen, 1990; Wu et al., 2001). However in
the case of direct compression binders, tabletability has to be
balanced with ﬂowability. High speciﬁc surface area and rugosity
may improve cohesion but it can be expected to negatively impact
powder ﬂow.
4.6. Degree of polymerization
There is no obvious correlation between the degree of
polymerization (DP) of MCC and its tabletability. It is merely an
identity test to distinguish MCC (DP < 350) from powdered
cellulose (DP > 440). Dybowski showed that the origin of the
raw materials and the production method more decisively
inﬂuence the characteristics of MCC than DP (Dybowski, 1997).
For the manufacturer, DP is only a criterion used to help guide the
hydrolysis of MCC, whereas for the user DP is a manner to distinct
between MCC and powdered cellulose.
Schlieout et al. claimed a correlation between DP and tablet
hardness based on two out of only three data points (Shlieout et al.,
2002). There was no difference between MCC with DPs of 244 and
299 but both were more tabletable than MCC with a DP of 190. Liao
et al. studied 16 MCC samples, including the high density grades
“301” and “302”, and concluded that DP positively impactstabletability (Liao et al., 2012). High bulk density grades are
obtained from special wood pulps characterized by lower level-off
DP, and should not be directly compared with standard grades.
This reﬂects the lack of distinction between degree of
polymerization (DP) and level-off degree of polymerization
(LODP). LODP is typical of a particular raw material, commonly
in the range 200–300 (Doelker, 1993), after which it is difﬁcult to
further hydrolyze the MCC. DP values higher than the level-off
degree of polymerization plateau are more difﬁcult to control due
to their greater sensitivity to hydrolysis conditions.
Above the LODP MCC retains more of the ﬁbrous cellulose
characteristics, which would result in a lower bulk density, may
improve tabletability but would hinder powder ﬂow (Wu et al.,
2001). Below the LODP MCC is less ﬁbrous, denser and less
tabletable. Tabletability is not related to a particular DP value; as an
example powdered cellulose has a higher DP than MCC but is not as
tabletable (Carlin, 2008). Within a single MCC grade, and in order
to meet DP and bulk density speciﬁcations, MCC manufacturers
need to tightly control the hydrolysis conditions to avoid producing
out of speciﬁcation (OOS) material.
4.7. Crystallinity
The wide range of reported values of degree of crystallinity for
microcrystalline cellulose (60–80%) could be explained by the
different methods used to determine this parameter, including X-
ray diffraction and infrared spectroscopy, but also by the method
of data manipulation and analysis (Landín et al., 1993a; Rowe
et al., 1994).
When a single method is selected, it has been reported that
crystallinity does not vary much between various MCCs (Pesonen
and Paronen, 1990; Suzuki and Nakagami, 1999; Williams et al.,
1997). This was conﬁrmed by similar sorption characteristics
when exposed to elevated humidity levels. Indeed considering
that the amorphous region is more hydrophilic, lower degrees of
crystallinity should result in higher equilibrium moisture
contents.
Modifying the hydrolysis conditions, including temperature,
time and acid concentration, also have very little impact on the
degree of crystallinity, i.e., the regularity of the arrangement of the
cellulose polymer chains (Shlieout et al., 2002; Wu et al., 2001).
This observation indicates that crystallinity cannot be controlled at
the hydrolysis stage. Crystallinity appears to be more dependent on
pulp source rather than on processing conditions (Landín et al.,
1993a), which is consistent with the method of MCC manufacture
where the acid preferentially attacks the (pulp dependent)
amorphous regions.
The impact of crystallinity on tabletability is far from obvious
(Gohel, 2005). Suzuki and Nakagami were able to reduce
crystallinity, from about 65% down to 12% (as measured by X-
ray diffraction), by pulverizing MCC using a vibrational rod mill
(Suzuki and Nakagami, 1999). Only then was it possible to observe
a reduction of tabletability. Reducing crystallinity to about 37%
reduced the dissolution rate of acetaminophen tablets, however
dissolution rates were increased compared to a standard MCC
when crystallinity became less than 26%.
The total amount of sorbed water in MCC is proportional to
the fraction of amorphous material (Amidon and Houghton,
1995; Bolhuis and Chowhan, 1996; Nokhodchi, 2005). Therefore
MCC powders with a lower degree of crystallinity may contain
more water than their counterparts with a higher degree. If
low-crystallinity MCC preferentially binds more water, moisture
sensitive APIs may exhibit lower rates of degradation (Vehovec
et al., 2012).
Despite the controversial impact of crystallinity, it may
inﬂuence the adsorption of water on cellulose microﬁbrils, which
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drug product (Pifferi et al., 1999).
5. Conclusions
Thanks to its ability to economically produce large batches of
tablets, DC remains one of the preferred techniques to produce oral
solid dosage forms. However DC is directly impacted by the raw
material attributes since these are not altered by preceding process
steps. MCC is widely recognized as one of the best tablet diluents.
Considering the scale of manufacture, MCC presents some
inevitable variability, which can be ampliﬁed by sourcing from
multiple sites or from multiple suppliers.
The deformation mechanism and the physico-chemical prop-
erties of MCC dictate its performance. The plasticity of MCC
together with its relatively low bulk density, high surface area and
high hygroscopicity explains its unique binding properties. When
compared to brittle excipients, MCC is more lubricant sensitive,
strain rate sensitive and cohesive.
QbD is driving the pharmaceutical industry to better under-
stand the impact of raw material variability on the performance
and manufacturability of new drug products. Considering the
number of excipients in formulations, the number of physico-
chemical parameters that may be studied, the difﬁculty of
obtaining or producing representative samples, and the inter-
actions with APIs and manufacturing processes, identifying
excipients’ CMAs is not an easy task.
There is evidence that moisture content, particle size, particle
shape, bulk density and surface area do inﬂuence the tableting
properties of MCC, i.e., tabletability and ﬂowability. However since
a criticality can only be conﬁrmed in a speciﬁc formulation and a
given application, drug manufacturers and excipients suppliers
need to work together in order to promote excipients and
processes understanding.
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